Biotechnology

PharmaNest to Present Five Digital Pathology and AI Communications at Digestive Disease Week 2026 Showcasing Advances in Fibrosis Research on IBD and EoE

April 24, 2026 3:00 PM

PharmaNest Inc., a leader in high-resolution quantitative digital pathology and artificial intelligence, announced today that it will present five abstracts at Digestive Disease Week 2026, taking place May 2-5, 2026. Developed in collaboration with academic and clinical partners, these presentations highlight the capabilities of PharmaNest's FibroNest™ digital pathology biomarkers in quantifying fibrosis and characterizing tissue remodeling...

Read more

Edison Oncology Presents New Preclinical Data on EO1001 and EO4426 Highlighting Differentiated Targeting of Cancer Resistance Pathways at AACR 2026

April 23, 2026 9:00 AM

Edison Oncology Holding Corp. ("Edison Oncology" or the "Company") today announced presentation of new preclinical data from its EO1001 and EO4426 programs at the American Association for Cancer Research (AACR) Annual Meeting 2026, that took place April 17-22, 2026 in San Diego, California. "This work highlights two mechanistically distinct programs designed to address biologically defined resistance pathways in cancer," said Jeffrey A. Bacha,...

Read more

Aspira Women's Health (OTCQB:AWHL) Enters Key Growth Phase with Molecular Lab Expansion to Accelerate Breakthrough Endometriosis Blood Test ENDOinform(TM)

April 23, 2026 8:55 AM

Aspira Women's Health Inc. ("Aspira") (OTCQB:AWHL), an AI-enhanced bio-analytics company focused on the development of noninvasive gynecologic disease diagnostics and disease management tools, today announced it is completing the buildout of its molecular laboratory in Q2 2026, marking a major operational milestone that accelerates development and future commercialization of its high-potential endometriosis diagnostic, ENDOinform™. This...

Read more

Lobe Sciences Ltd. Comments on White House Executive Order Supporting Drug Development for Neurological and Mental Health Disorders

April 23, 2026 8:00 AM

Lobe Sciences Ltd. ("Lobe Sciences" or the "Company") (CSE:LOBE)(OTCQB:LOBEF)(FWB:LOBE.F), a clinical-stage biopharmaceutical company focused on advancing therapies for diseases with significant unmet medical needs, welcomes the recent White House Executive Order supporting the advancement of novel treatments for neurological and mental health disorders. The Company believes the Executive Order represents an important step toward enabling...

Read more

Alligator Bioscience Comments on Henlius Presentation of HLX49 Preclinical Data at AACR 2026

April 23, 2026 4:20 AM

Alligator Bioscience (Nasdaq Stockholm:ATORX) today announced that Shanghai Henlius Biotech, Inc. has presented preclinical data for HLX49, a HER2 biparatopic antibody-drug conjugate (ADC), at the American Association for Cancer Research (AACR) Annual Meeting 2026, held in San Diego, USA, from 17-22 April 2026. HLX49 is a HER2 biparatopic antibody-drug conjugate (ADC) that incorporates HER2 binding domains from HLX22, a HER2-specific monoclonal...

Read more

ClearPoint Neuro Announces FDA Clearance of the Velocity Alpha(R) MR High Speed Surgical Drill System and First Clinical Use, Further Expanding Our Drug Delivery Ecosystem and Global Footprint

April 22, 2026 4:05 PM

ClearPoint Neuro, Inc. (NASDAQ:CLPT) ("Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced the successful completion of the first clinical procedure utilizing the 510(k)-cleared Velocity Alpha MR High Speed Surgical Drill System. Utilized in a four-trajectory clinical trial procedure, the system highlights its scalability and potential to support a broader range...

Read more

Xenetic Biosciences, Inc. Announces Abstract Acceptance for Presentation at the 2026 ASCO Annual Meeting

April 22, 2026 9:00 AM

Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers, today announced that its abstract has been accepted for presentation at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 29 - June 2, 2026, in Chicago, IL. The accepted abstract, titled "Targeting cfDNA and...

Read more

IGC Pharma Adds Kerwin Medical Center in Dallas to Phase 2 CALMA Trial as Enrollment Advances Toward Completion

April 22, 2026 8:30 AM

IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company"), a clinical-stage biotechnology company developing therapeutics for Alzheimer's disease, today announced the addition of Kerwin Medical Center in Dallas, Texas as a clinical site in the Company's Phase 2 CALMA trial evaluating IGC-AD1 for agitation in Alzheimer's disease. The Company recently reported approximately 80% enrollment in CALMA and continues to advance toward enrollment...

Read more

Faron Pharmaceuticals Ltd: Holding(s) in Company

April 22, 2026 7:45 AM

Faron Pharmaceuticals (HEL:FARON)(LSE:FARN) TR-1: Standard form for notification of major holdings NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i 1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached ii: Faron Pharmaceuticals OY 1b. Please indicate if the issuer is a non-UK issuer (please mark with an "X" if appropriate)...

Read more

Vicore Pharma Completes Enrollment in the Phase 2b ASPIRE Trial of Buloxibutid in Idiopathic Pulmonary Fibrosis

April 22, 2026 2:20 AM

Vicore Pharma Holding AB (Nasdaq Stockholm:VICO), unlocking the potential of a novel class of drugs, angiotensin II type 2 receptor agonists (ATRAGs), today announced completion of enrollment in the global Phase 2b ASPIRE trial evaluating buloxibutid for the treatment of IPF. The ASPIRE trial successfully enrolled more than 360 patients across over 100 sites in 14 countries, including 29 sites in the United States. Full trial enrollment was...

Read more

Data4Cure Presents a Foundation Model for Forward and Reverse Translation at AACR 2026 Annual Meeting

April 21, 2026 2:00 PM

Data4Cure, Inc., the company behind the Biomedical Intelligence® Cloud for pharmaceutical R&D, today announced the upcoming presentation of two late-breaking poster abstracts at the 2026 American Association for Cancer Research (AACR) Annual Meeting in San Diego, CA. The posters describe RNA1-DA, a new domain-adaptive extension of the company's RNA1 foundation model, designed to enable forward and reverse translation between clinical tumors and...

Read more

BioInvent to Present Data of BI-1808 Plus KEYTRUDA(R) (Pembrolizumab) in Recurrent Ovarian Cancer at the 2026 ASCO Annual Meeting

April 21, 2026 10:25 AM

BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV), a leader in the discovery of novel immune-modulatory antibodies, today announced that additional clinical data from its ongoing Phase 2a study evaluating BI-1808 in combination with MSD's (Merck & Co., Inc., Rahway, NJ., USA) anti-PD-1 therapy, KEYTRUDA® (pembrolizumab), in advanced ovarian cancer has been selected for a poster presentation at the 2026 American Society of Clinical...

Read more

Lobe Sciences Ltd. Engages Massive Intelligence Pty Ltd for Investor Relations and Corporate Communications Services

April 21, 2026 6:00 AM

Lobe Sciences Ltd. ("Lobe Sciences" or the "Company") (CSE:LOBE)(OTCQB:LOBEF)(FWB:LOBE), a clinical stage biopharmaceutical company focused on developing products to treat diseases with significant unmet medical needs, is pleased to announce that it has engaged Massive Intelligence Pty Ltd ("Massive Intelligence") to provide investor relations and corporate communications services. Pursuant to an engagement letter dated April 15th 2026, the...

Read more

LIR Life Sciences Corp. Announces Agreement with Resilience BioSciences Inc.

April 20, 2026 6:00 PM

LIR Life Sciences Corp. (CSE:SKNY)(OTC PINK:BBCMF)(Frankfurt:N790) (WKN: A41QA9) ("LIR" or the "Company") is pleased to announce that it has entered into a Technology Development Collaboration Agreement (the "Agreement") with Resilience BioSciences Inc. ("RBI"), a Vancouver-based drug discovery and development company, to support and expand LIR's ongoing preclinical research activities. Under the Agreement, LIR intends to collaborate with RBI's...

Read more

ClearPoint Neuro Announces Canadian Approval for its Navigation System Further Expanding Our Drug Delivery Ecosystem and Global Footprint

April 20, 2026 4:05 PM

ClearPoint Neuro, Inc. (NASDAQ:CLPT) ("Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced receipt of a Medical Device License (MDL) from Health Canada for its Neuro Navigation System, further expanding our Drug Delivery ecosystem and global footprint. Covering both ClearPoint MRI-guidance and new iCT-guidance workflows in Canada, the MDL builds on the previously...

Read more

Biomind Labs Applauds Landmark Executive Order Accelerating Psychedelic Research and Access in The United States

April 20, 2026 8:30 AM

Biomind Labs Inc. ("Biomind" or the "Company") (CBOE:BMND)(OTC PINK:BMNDF)(FRA:3XI), a clinical-stage bio-pharmaceutical company focused on transforming breakthroughs in neuroscience and biomedical research into novel pharmaceutical drugs, today welcomes the historic executive order signed by President Trump to accelerate research, regulatory pathways, and patient access to psychedelic treatments. This landmark policy shift marks a turning...

Read more

IGC Pharma Secures Psilocybin Research Authorization, Expanding Focus on Neuropsychiatric Symptoms in Dementia

April 20, 2026 8:30 AM

IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company"), a clinical-stage biotechnology company developing therapeutics for Alzheimer's disease, today announced that on April 9, 2026, it received authorization in Colombia to synthesize, formulate, and conduct development activities involving psilocybin at its research and development facility in Bogotá. The authorization, granted under the oversight of the Fondo Nacional de...

Read more

Microbix Engages with Diagnostics Industry Experts

April 20, 2026 7:00 AM

Microbix Biosystems Inc. (TSX:MBX)(OTCQX:MBXBF, Microbix®), a life sciences innovator, manufacturer, and exporter, announces it is releasing three episodes of the second season of its podcast titled "Diagnostics: Beyond the Lab." This Microbix podcast series engages with third-party experts to discuss opportunities and challenges facing the diagnostics industry - to inform policy-makers, medical or scientific professionals, and patients. The...

Read more

Lobe Sciences Ltd. Announces Closing of Non-Brokered Private Placement and Provides Corporate Update

April 20, 2026 6:00 AM

Lobe Sciences Ltd. ("Lobe" or the "Company") (CSE:LOBE)(OTCQB:LOBEF)(Frankfurt:LOBE) is pleased to announce the closing of its previously announced non-brokered private placement offering of 14,615,384 common shares in the capital of the Company ("Common Shares") at a price of $0.065 per Common Share, for aggregate gross proceeds of approximately $950,000 (the "Private Placement"). The Company intends to use the proceeds of the Private Placement...

Read more

Faron Pharmaceuticals Ltd: Holding(S) In Company

April 20, 2026 3:35 AM

Faron Pharmaceuticals (HEL:FARON)(LSE:FARN) - FARON PHARMACEUTICALS LTD: HOLDING(S) IN COMPANY TR-1: Standard form for notification of major holdings NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i 1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached ii: Faron Pharmaceuticals OY 1b. Please indicate if the issuer is a...

Read more